Summary
HR+/HER2- breast cancer continues to represent a major target indication for SERDs, with approximately 481,000 cases reported in 2024 in the 7MM.
High-profile failures from Sanofi (amcenestrant) and a long list of early-stage candidates such as GDC-029, AZD9496, GDC-0927, ZnC5, LSZ-102, brinalestrant (GDC-0810), and rintodestrant forced the field to reckon with hard lessons.
The turning point came with elacestrant (ORSERDU), the first-ever approved oral SERD in January 2023, followed by Eli Lilly's imlunestrant (INLURIYO) in September 2025.
The oral SERD pipeline is among the most active in oncology today, with agents such as camizestrant (A...
